BridgeMD
New treatment option for Type 2 Diabetes
Official title A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
ClinicalTrials.gov ID: NCT06627322
What this study is testing
What is Dual-combination therapy?
Dual-combination therapy is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for type 2 diabetes.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- ≥19 years of age
- Patient agreed to participate in the study and signed a written informed consent form
- Type 2 diabetes (ADA criteria)
- HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was...
- Any of the following: A. Patients who one or more of the following conditions
You likely can't join if
- Type 1 diabetes
- Estimated GFR\<45 ml/min/1.73m²
- AST or ALT greater than 3 times the normal upper limit
- Symptomatic heart failure (NYHA Class III or IV)
- History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent
- Currently in active treatment for malignancy
See the full eligibility criteria
- ≥19 years of age
- Patient agreed to participate in the study and signed a written informed consent form
- Type 2 diabetes (ADA criteria)
- HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was administered) with oral antidiabetic drugs (OADs)
- Any of the following: A. Patients who one or more of the following conditions
- Coronary artery disease
- Atherosclerotic ischemic stroke, transient ischemic attack, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm
- Prevalence of diabetes ≥10 years
- Left ventricular hypertrophy
- Albuminuria
- Chronic kidney disease (eGFR\<60mL/min/1.73m²)
- Diabetic Retinopathy
- Diabetic neuropathy or B. Patients who have two or more of the following cardiovascular risk factors (1) Family history of early-onset ASCVD (first-degree relatives with disease before age 55 for men and before age 65...
- Type 1 diabetes
- Estimated GFR\<45 ml/min/1.73m²
- AST or ALT greater than 3 times the normal upper limit
- Symptomatic heart failure (NYHA Class III or IV)
- History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent
- Currently in active treatment for malignancy
- Contraindications for each assigned drug, as applicable
- Pregnant and nursing women
- If the investigator determines that assignment to the standard glycemic control arm raises ethical concerns
The study team makes the final eligibility decision.
Where it's taking place
- Daegu, South Korea
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Daegu, South Korea; Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.